Sollis Therapeutics
Columbus, US · Founded 2017 · Delaware corporation · 26 employees on LinkedIn
Founders & leadership
AD
Alex DiNelloNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$5M disclosed across 2 rounds · 2020–2021
▶$2.5MraisedMar 2021 · 2 investors · BiotechnologyRule 506(c)
▶$2.5MraisedMar 2021 · 2 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Alex DiNelloExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06c
▶$2.5MraisedAug 2020 · 3 investors · BiotechnologyRule 506(c)
▶$2.5MraisedAug 2020 · 3 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Alex DiNelloExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Proceeds to insiders
- $30K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Sollis Therapeutics raised?
- Sollis Therapeutics has disclosed $5M raised across 2 rounds.
- Where is Sollis Therapeutics headquartered?
- Sollis Therapeutics is headquartered in Columbus, US.